Altimmune's Pemvidutide Shows Promise in Phase 2 Trial for Alcohol Use Disorder

Altimmune announced positive topline results Monday from its Phase 2 RECLAIM trial evaluating pemvidutide, a dual glucagon/GLP-1 receptor agonist, in patients with moderate to severe alcohol use disorder. The investigational drug achieved statistically significant reductions in heavy drinking days compared to placebo, meeting its primary endpoint and several key secondary measures that could position it as a breakthrough treatment for the estimated 28 million American adults living with AUD.

Significant Reduction in Heavy Drinking Days

The RECLAIM trial enrolled approximately 100 patients with moderate to severe alcohol use disorder and body mass index greater than 25 kg/m², randomizing them to receive either 2.4 mg of pemvidutide or placebo once weekly for 24 weeks. The study met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week versus placebo, with a p-value of 0.0014.

Patients receiving pemvidutide experienced a mean reduction of 4.20 heavy drinking days per week from baseline, compared to 2.75 days for those on placebo—a difference of 1.45 days representing a meaningful clinical improvement in drinking behavior.

Secondary Endpoints Demonstrate Broad Efficacy

Beyond the primary endpoint, pemvidutide showed consistent positive results across multiple secondary measures recognized by the FDA as registrational endpoints. Nearly two-thirds of patients treated with pemvidutide, 64.4 percent, achieved a two-level reduction in World Health Organization Risk Drinking Levels compared to 34.8 percent of placebo patients. This outcome carries particular significance as it represents a clinically meaningful shift in drinking patterns that reduces long-term health risks.

Additionally, 42.2 percent of pemvidutide-treated patients achieved zero heavy drinking days during weeks 21 through 24, compared to just 17.4 percent in the placebo group. The treatment also produced statistically significant improvements in the percentage of days with abstinence and reductions in phosphatidylethanol levels, an objective serum biomarker of alcohol intake.

Favorable Safety Profile Observed

Pemvidutide demonstrated a generally favorable tolerability profile consistent with its mechanism of action as a GLP-1 receptor agonist. The majority of adverse events were mild to moderate in severity, with gastrointestinal symptoms being the most commonly reported. Nausea occurred in 44 percent of pemvidutide patients compared to 24 percent on placebo, while vomiting was reported by 18 percent versus 6 percent.

Treatment discontinuation rates were comparable between groups, with 20 percent of pemvidutide patients and 22 percent of placebo patients discontinuing the study. Only 10 percent of pemvidutide discontinuations were attributed to study drug-related adverse events.

Addressing a Critical Unmet Need

Despite affecting an estimated 28 million American adults, alcohol use disorder remains dramatically undertreated. Only three medications currently carry FDA approval for AUD—disulfiram, naltrexone, and acamprosate—and these agents are used by less than 2 percent of affected patients. Their limited adoption reflects modest efficacy, challenging side effect profiles, and the persistent stigma that surrounds addiction treatment.

Pemvidutide represents a novel approach that targets both the metabolic and neurobiological dimensions of alcohol use disorder. As a balanced dual agonist of glucagon and GLP-1 receptors, the drug may offer advantages over existing treatments by addressing the liver damage commonly associated with heavy drinking while simultaneously reducing cravings through effects on reward pathways.

The GLP-1 Connection to Addiction Treatment

The positive RECLAIM results add to growing evidence that GLP-1 receptor agonists, the drug class that includes diabetes and obesity treatments like Ozempic and Wegovy, may have broader applications in addiction medicine. Previous research has suggested these medications can reduce cravings for alcohol, opioids, and other substances by modulating dopamine-driven reward pathways in the brain.

Altimmune's pemvidutide distinguishes itself within this class through its additional activation of glucagon receptors, which produce direct effects on the liver including reductions in fat accumulation, inflammation, and fibrosis. Given that alcohol-associated liver disease represents a major complication of AUD, this dual mechanism could provide particular benefit for patients with concurrent metabolic dysfunction.

Path Forward Toward Regulatory Approval

Based on the RECLAIM results, Altimmune plans to request an End-of-Phase 2 meeting with the FDA to discuss the regulatory path forward for pemvidutide in alcohol use disorder. The company has already received Fast Track designation for this indication, which should facilitate expedited review of future filings.

The FDA has previously recognized two-level reduction in WHO Risk Drinking Levels and achievement of zero heavy drinking days as acceptable endpoints for AUD drug registration, suggesting pemvidutide's demonstrated efficacy on these measures could support a future New Drug Application.

Implications for the Addiction Treatment Landscape

If approved, pemvidutide would become the first new pharmacological treatment for alcohol use disorder in nearly two decades and the first to leverage the GLP-1 receptor mechanism. Its weekly injection formulation could improve adherence compared to daily oral medications, while its metabolic benefits might appeal to the substantial proportion of AUD patients who also struggle with obesity or liver disease.

The RECLAIM results arrive amid renewed scientific and public interest in pharmacological treatments for addiction, driven in part by the success of medication-assisted treatment for opioid use disorder and emerging evidence for GLP-1 drugs across multiple substance use disorders. For the millions of Americans whose lives are affected by alcohol addiction, pemvidutide offers the possibility of a new therapeutic option that addresses both the behavioral and physiological dimensions of this challenging condition.